InvestorsHub Logo
Followers 10
Posts 1578
Boards Moderated 0
Alias Born 10/15/2014

Re: None

Tuesday, 11/11/2014 6:19:03 PM

Tuesday, November 11, 2014 6:19:03 PM

Post# of 47873
Now that the IDIQ has been signed up, I think Implant will be a much more attractive buyout candidate. I’ve seen a lot a stuff posted about $5 or $10 stock prices, and that seems a little overly optimistic to me. I'm happy to be wrong on this one, so I’m curious to hear what people believe would be a fair price.

My ballpark figure for a purchase price would be around $500 million for the enterprise, which I figure would lead to a per share price of around $2.60 per share. I got there by dividing A by B, where:

“A” equals $500 million minus $20 million BAM Note and $14 million Management Change of Control Plan =$466 million; and

“B” equals 69 million shares outstanding, plus 67 million shares issuable on conversion of $3.184 million principal and $2.175 million accrued interest on Sr. Convertible Note ($0.08 per share conversion) plus 11 million shares issuable from $12 million Senior Secured Note (convertible to Series H preferred stock which converts to common at $1.09 a share); plus 10 million shares issuable from $12 million Senior Secured Note (convertible to Series I preferred stock which converts to common at $1.18 per share); plus 18 million convertible employee stock options plus 4 million convertible warrants=179 million shares.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.